Bariatric surgery requires permanent changes in the approach to administration of pharmaceuticals, lifestyle, and medical care.
Summary
Bariatric surgery is currently recommended only for adolescents and adults who are severely overweight and have comorbid conditions. Often, obesity-related health problems improve or disappear after the weight is lost. As a life changing event, bariatric surgery requires permanent changes in the approach to health care. Postsurgical selection of medication will be quite different from therapeutic regimen options prior to surgery. In addition, bariatric surgery has resulted in reduction of medication intake associated with obesity-related comorbid disease. Patients will require detailed education to ensure awareness regarding medication-related precautions.
Conclusion
Options described in this article will assist the health care team to individually tailor medications to meet the needs of the unique post-bariatric surgery patient population.
St. PeterSD, CraftRO, TiedeJL, SwainJM. Impact of advanced age on weight loss and health benefits after laparoscopic gastric bypass. Arch Surg.2005; 140(2): 165–168.
10.
Greenway SE, Greenway FL 3rd, KleinS.Effects of obesity surgery on non-insulin-dependent diabetes mellitus. Arch Surg.2002; 137(10): 1109–1117.
11.
National Institutes of Health.Gastrointestinal surgery for severe obesity. Consensus Development Conference Panel. Ann Intern Med.1991; 115(12): 956–961.
12.
American Society for Bariatric Surgery.www.asbs.org. Accessed July 23, 2006.
BadmanM.K., FlierJ.S.The gut and energy balance: visceral allies in the obesity wars. Science.2005; 307(5717): 1909–1914.
16.
LeMontD., MooreheadM.K., ParishM.S.. Suggestions for the pre-surgical psychological assessment of bariatric surgery candidates. American Society for Bariatric Surgery; October 2004. http://www.asbs.org/html/pdf/PsychPreSurgicalAssessment.pdf. Accessed November 20, 2007.
17.
VirjiA., MurrM.M.Caring for patients after bariatric surgery. Am Fam Physician.2006; 73(8): 1403–1408.
18.
ChanF.K., ChingJ.Y., HungL.C.. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med.352(3): 238–244.
SchauerP., BurgueraB., IkramuddinS.. Effect of laparoscopic Roux-En Y gastric bypass on type 2 diabetes mellitis. Ann Surg.2003; 238(4): 467–485.
24.
JosephB., GenawJ., CarlinA., JordanJ., TalleyJ., RubinfeldI.Perioperative tight glycemic control: the challenge of bariatric surgery patients and fear of hypoglycemic events. Permanente J.2007; 11(2): 36–39.
25.
EdmistonC.E., KrepelC., KellyH.. Perioperative antibiotic prophylaxis in the gastric bypass patient: do we achieve therapeutic levels?Surgery.2004; 136(4): 738–747.
26.
GonzalezQ.H., TishlerD.S., Plata-MunozJ.J.. Incidence of clinically evident deep veinous thrombosis after laparoscopic Roux-en-Y gastric bypass. Surg endosc.2004; 18(7): 1082–1084.
27.
FeldJ.M., HoffmanW.E., StechertM.M., HoffmanI.W., AnandaR.C.Fentanyl or dexmedetomidine combined with desflurane for bariatric surgery. J Clin Anesth.2006; 18(1): 24–28.
GordonK.B., LangleyR.G., LeonardiC.. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double blind, randomized controlled trial and open label extension study. J Am Acad Dermatol.2006; 55(4): 598–606.
38.
American Society for Metabolic and Bariatric Surgery.www.asbs.org. Accessed October 19, 2005.
39.
U.S. Food and Drug Administration.Cox 2 selective and non-selective nonsteroidal anti-inflammatory drugs.http://www.fda.gov/cder/drug/infopage/cox2/. Accessed November 19, 2007.
40.
University of Pennsylvania Health System. Penn Bariatric surgery program. http://pennhealth.com/bariatrics/. Accessed November 19, 2007.
41.
GouldJ.C., GarrenM.J., StarlingJ.R.Laparoscopic gastric bypass results in decreased prescription medication costs within 6 months. J Gastrointest Surg.2004; 8(8): 983–987.
42.
The American Medical Association Roadmaps on: The Treatment of Obesity. The AMA Publication on Surgical Management. Oxford University Press; New York, NY: November 2003, Booklet 7.
43.
MaloneM., Alger-MayerS.A.Medication use patterns after gastric bypass surgery for weight managementAnn Pharmacother.2005; 39(4): 637–642.
44.
PotteigerC.E., ParagiP.R., InversoN.A.. Bariatric surgery: shedding the monetary weight of prescription costs in the managed care arena. Obes Surg.2004; 14(6): 725–730.
45.
le RouxC., AylwinS.J., BatterhamR.L.. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss and improve metabolic parameters. Ann Surg.2006; 243(1): 108–114.
46.
BeckwithM.C., FeddemaS.S., BartonR.G., GravesC.A guide to drug therapy in patients with enteral feeding tubes: dosage form selection and administration methods. Hosp Pharm.2004; 39(3): 225–237.
47.
MitchellJ.F., LeadyM.A.Oral dosage forms that should not be crushed. Hosp Pharm.2004; 39(4) issue insert. [Wall Chart].
48.
Red Book, 109th ed.Montvale, NJ: Thomson Healthcare/Thomson PDR: 2005.
